Latest Insider Transactions at Orasure Technologies Inc (OSUR)
This section provides a real-time view of insider transactions for Orasure Technologies Inc (OSUR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ORASURE TECHNOLOGIES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ORASURE TECHNOLOGIES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2022
|
Agnieszka Gallagher General Counsel & CCO |
BUY
Grant, award, or other acquisition
|
Direct |
38,050
+29.58%
|
$304,400
$8.86 P/Share
|
|
Feb 01
2022
|
Stephen S Phd Tang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,321
-2.69%
|
$242,568
$8.86 P/Share
|
|
Feb 01
2022
|
Stephen S Phd Tang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
119,913
+14.32%
|
$959,304
$8.86 P/Share
|
|
Feb 01
2022
|
Lisa Nibauer President of Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
34,556
+21.65%
|
$276,448
$8.86 P/Share
|
|
Feb 01
2022
|
Lisa Nibauer President of Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,606
-2.8%
|
$20,848
$8.86 P/Share
|
|
Feb 01
2022
|
Michele Marie Miller SVP Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
6,772
+9.49%
|
$54,176
$8.86 P/Share
|
|
Feb 01
2022
|
Michele Marie Miller SVP Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,662
-0.94%
|
$13,296
$8.86 P/Share
|
|
Feb 01
2022
|
Kathleen Gallagher Weber Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,526
-1.31%
|
$76,208
$8.86 P/Share
|
|
Feb 01
2022
|
Kathleen Gallagher Weber Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,050
+8.84%
|
$328,400
$8.86 P/Share
|
|
Feb 01
2022
|
Scott Gleason Interim CFO/SVP IR |
BUY
Grant, award, or other acquisition
|
Direct |
29,345
+22.95%
|
$234,760
$8.86 P/Share
|
|
Jan 05
2022
|
Lisa Nibauer President of Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
60,901
+39.54%
|
$487,208
$8.21 P/Share
|
|
Jan 05
2022
|
Kathleen Gallagher Weber Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,901
+25.87%
|
$487,208
$8.21 P/Share
|
|
Jan 05
2022
|
Michele Marie Miller SVP Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
42,631
+41.74%
|
$341,048
$8.21 P/Share
|
|
Jan 05
2022
|
Scott Gleason Interim CFO/SVP IR |
BUY
Grant, award, or other acquisition
|
Direct |
48,721
+41.33%
|
$389,768
$8.21 P/Share
|
|
Dec 31
2021
|
Jack E Jerrett SVP General Counsel & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,320
-4.89%
|
$162,560
$8.81 P/Share
|
|
Dec 22
2021
|
James A Datin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,717
+5.52%
|
$15,453
$9.46 P/Share
|
|
Nov 29
2021
|
Agnieszka Gallagher General Counsel & CCO |
BUY
Grant, award, or other acquisition
|
Direct |
52,534
+41.67%
|
$472,806
$9.52 P/Share
|
|
Nov 08
2021
|
Nancy J Gagliano Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,563
+50.0%
|
$95,067
$9.94 P/Share
|
|
Nov 08
2021
|
Anne Clem Whitaker Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,563
+50.0%
|
$95,067
$9.94 P/Share
|
|
Sep 30
2021
|
James A Datin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,404
+4.83%
|
$15,444
$11.58 P/Share
|
|
Aug 12
2021
|
James A Datin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,673
-12.05%
|
$40,403
$11.15 P/Share
|
|
Jun 30
2021
|
James A Datin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,589
+4.96%
|
$15,890
$10.23 P/Share
|
|
May 18
2021
|
Ronny B Lancaster Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+23.95%
|
$98,568
$9.59 P/Share
|
|
May 18
2021
|
Eamonn P Hobbs Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+19.98%
|
$98,568
$9.59 P/Share
|
|
May 18
2021
|
Lelio Marmora Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+37.87%
|
$98,568
$9.59 P/Share
|
|
May 18
2021
|
Michael Celano Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,559
+14.74%
|
$122,031
$9.59 P/Share
|
|
May 18
2021
|
James A Datin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+27.49%
|
$98,568
$9.59 P/Share
|
|
May 18
2021
|
David Shulkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+30.59%
|
$98,568
$9.59 P/Share
|
|
May 18
2021
|
Mara G. Aspinall Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,952
+23.36%
|
$98,568
$9.59 P/Share
|
|
May 17
2021
|
Eamonn P Hobbs Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,446
-4.21%
|
$13,014
$9.5 P/Share
|
|
May 17
2021
|
Michael Celano Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,041
-3.05%
|
$18,369
$9.5 P/Share
|
|
May 17
2021
|
James A Datin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,798
-9.11%
|
$16,182
$9.5 P/Share
|
|
May 17
2021
|
David Shulkin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-10.6%
|
$14,832
$9.5 P/Share
|
|
May 17
2021
|
Mara G. Aspinall Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,775
-6.63%
|
$15,975
$9.5 P/Share
|
|
May 11
2021
|
Lisa Nibauer President of Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,606
-4.75%
|
$14,454
$9.55 P/Share
|
|
May 07
2021
|
Roberto Cuca CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,763
-2.06%
|
$42,867
$9.85 P/Share
|
|
May 07
2021
|
Roberto Cuca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,740
+8.33%
|
$96,660
$9.85 P/Share
|
|
Mar 31
2021
|
James A Datin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,401
+6.63%
|
$15,411
$11.6 P/Share
|
|
Feb 01
2021
|
Stephen S Phd Tang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
73,342
+21.99%
|
$1,100,130
$15.55 P/Share
|
|
Feb 01
2021
|
Stephen S Phd Tang President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,904
-3.28%
|
$193,560
$15.55 P/Share
|
|
Feb 01
2021
|
Roberto Cuca CFO |
BUY
Grant, award, or other acquisition
|
Direct |
24,706
+18.5%
|
$370,590
$15.55 P/Share
|
|
Feb 01
2021
|
Roberto Cuca CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,221
-4.03%
|
$108,315
$15.55 P/Share
|
|
Feb 01
2021
|
Kathleen Gallagher Weber Chief Product Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,134
-1.8%
|
$107,010
$15.55 P/Share
|
|
Feb 01
2021
|
Kathleen Gallagher Weber Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,224
+9.62%
|
$363,360
$15.55 P/Share
|
|
Feb 01
2021
|
Lisa Nibauer President of Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
19,769
+36.88%
|
$296,535
$15.55 P/Share
|
|
Feb 01
2021
|
Jack E Jerrett SVP General Counsel & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,889
-2.21%
|
$178,335
$15.55 P/Share
|
|
Feb 01
2021
|
Jack E Jerrett SVP General Counsel & CCO |
BUY
Grant, award, or other acquisition
|
Direct |
23,256
+7.42%
|
$348,840
$15.55 P/Share
|
|
Feb 01
2021
|
Michele Marie Miller SVP Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
3,410
+16.8%
|
$51,150
$15.55 P/Share
|
|
Feb 01
2021
|
Michele Marie Miller SVP Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,387
-3.19%
|
$20,805
$15.55 P/Share
|
|
Dec 23
2020
|
Kathleen Gallagher Weber Chief Product Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.39%
|
$110,000
$11.76 P/Share
|